Skip to main content
. 2023 Dec 20;40(4):e2023049. doi: 10.36141/svdld.v40i4.15055

Table 3.

Comparison of pulmonary function test, DLCO, and 6MWT results before the treatment, at 1st and 6th months of treatment in patients receiving immunosuppressive therapy.

Admission 1st month 6th month F p difference
SpO2 % 90,09±5,22 94,1±3,13 95,88±2 22,285 <0,001 Pre<1<6
FVC (L) 2,43±0,98 2,85±1 2,75±1,01 5,795 0,006 Pre<1,6
FVC % 68,06±19,09 73,95±16,76 77,48±18,11 12,262 0,001 Pre<1<6
FEV1 (L) 2,17±0,81 2,48±0,88 2,36±0,89 3,356 0,045 -
FEV1 % 73,81±19,37 79,5±20,56 81,16±20,62 6,024 0,005 Pre<1,6
FEV1/FVC 91,38±13,05 89,23±9,35 87,39±11,2 0,081 0,922 -
DLCO 8,46±7,17 9,23±5,13 11,53±6,25 1,947 0,172 -
DLCO % 45,1±18,7 47,95±16,3 54,87±23,46 5,123 0,011 Pre<1,6
6MWT (meter) 368,11±153,49 416,91±160,44 435,32±153,22 2,964 0,086 -
6MWT Pre SpO2 % 94,32±2,71 94,91±3,07 95,41±3,31 0,172 0,765 -
6MWT Post SpO2 % 89,18±7,07 89,87±8,38 90,67±8,91 0,244 0,785 -

Abbreviations: SpO2: oxygen saturation as measured by pulse oximetry; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide; 6MWT: 6-minute walk test. Data are presented as mean±standard deviation unless otherwise stated.